Profile data is unavailable for this security.
About the company
Medacta International SA is a Swiss-based company specialized in medical devices. The Company develops, manufactures and distributes orthopaedic and neurosurgical medical devices. The Company designs a number of products, such as hip products, including hip replacement, hip anatomy, hip diseases, and other products for the preparation of hip surgery; knee product, which encompasses knee anatomy, knee diseases, knee replacement, the stability of the knee and for the preparation of knee surgery; shoulder product, which includes shoulder anatomy, shoulder disease, shoulder replacement, and for the preparation of shoulder operation, and spine product, which includes products for spinal treatments, spinal anatomy and for surgery, among others. Additionally, the Company also offers training and support to healthcare professionals.
- Revenue in CHF (TTM)509.33m
- Net income in CHF52.60m
- Incorporated2018
- Employees1.83k
- LocationMedacta Group SAStrada Regina 34CASTEL SAN PIETRO 6874SwitzerlandCHE
- Websitehttp://www.medacta.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Xvivo Perfusion AB | 60.53m | 16.47m | 1.15bn | 161.00 | 68.85 | 6.85 | 51.70 | 19.01 | 6.58 | 6.58 | 24.07 | 66.13 | 0.3325 | 1.14 | 4.67 | 4,691,194.00 | 9.05 | 1.24 | 9.68 | 1.33 | 74.41 | 73.14 | 27.21 | 4.76 | 4.23 | -- | 0.0117 | 0.00 | 43.88 | 26.04 | 398.29 | 48.57 | 21.35 | -- |
| AddLife AB | 807.45m | 9.44m | 1.28bn | 2.36k | 140.51 | 3.21 | 15.15 | 1.59 | 0.9601 | 0.9601 | 82.16 | 42.09 | 0.7625 | 3.50 | 5.58 | 4,351,152.00 | 0.9063 | 5.31 | 1.29 | 8.83 | 37.30 | 36.89 | 1.19 | 5.79 | 0.638 | 1.66 | 0.5146 | 31.73 | 6.62 | 31.30 | -60.42 | 8.00 | 44.43 | -1.89 |
| Oxford Nanopore Technologies PLC | 188.87m | -179.09m | 1.54bn | 1.28k | -- | 2.17 | -- | 8.16 | -0.187 | -0.187 | 0.197 | 0.662 | 0.2265 | 0.7333 | 2.86 | 135,499.20 | -21.47 | -21.12 | -24.63 | -24.67 | 53.89 | 53.90 | -94.82 | -81.85 | 3.36 | -- | 0.0747 | -- | -14.57 | 39.15 | -69.74 | -- | 8.92 | -- |
| SKAN Group AG | 344.01m | 32.24m | 1.77bn | 1.42k | 55.22 | 10.23 | 38.21 | 5.15 | 1.43 | 1.43 | 15.24 | 7.70 | 0.9179 | 0.6845 | 12.01 | 247,846.50 | 9.03 | 7.56 | 18.78 | 14.95 | 74.07 | 73.24 | 9.84 | 9.63 | 0.5813 | 38.46 | 0.0341 | 24.09 | 15.55 | 118.77 | 38.59 | 35.49 | -- | -- |
| Elekta AB (publ) | 1.46bn | 91.37m | 1.89bn | 4.57k | 21.43 | 2.27 | 10.14 | 1.29 | 2.96 | 2.96 | 47.38 | 28.01 | 0.5822 | 3.16 | 2.89 | 3,903,469.00 | 3.65 | 4.19 | 6.53 | 7.51 | 36.76 | 39.03 | 6.27 | 7.37 | 0.7425 | 3.91 | 0.4196 | 68.60 | 7.41 | 5.98 | 38.07 | 1.68 | 20.06 | 5.92 |
| Embla Medical hf | 744.50m | 61.19m | 1.91bn | 4.00k | 31.42 | 2.75 | 17.45 | 2.57 | 1.13 | 1.13 | 13.76 | 12.95 | 0.5755 | 2.23 | 6.65 | 1,483,676.00 | 4.75 | 4.06 | 5.51 | 4.76 | 62.02 | 62.47 | 8.25 | 6.91 | 1.26 | 6.59 | 0.4074 | 3.99 | 9.33 | 5.09 | 37.34 | -6.05 | 6.50 | -- |
| Medacta Group SA | 509.33m | 52.60m | 2.24bn | 1.83k | 42.57 | 6.95 | 20.22 | 4.40 | 2.63 | 2.63 | 25.49 | 16.14 | 0.7908 | 0.85 | 5.62 | 294,410.60 | 8.17 | 7.89 | 10.36 | 10.57 | 67.93 | 70.43 | 10.33 | 10.09 | 0.845 | 11.02 | 0.4015 | 17.01 | 16.85 | 13.38 | 2.41 | 0.6937 | 8.32 | -- |
| Gerresheimer AG | 1.88bn | 106.98m | 2.40bn | 12.01k | 22.41 | 1.79 | 8.24 | 1.27 | 3.31 | 3.31 | 58.26 | 41.47 | 0.5816 | 3.93 | 6.93 | 172,572.90 | 3.36 | 3.31 | 4.60 | 4.75 | 29.09 | 29.72 | 5.78 | 5.94 | 0.4635 | 4.29 | 0.4634 | 42.68 | 9.54 | 7.79 | 20.81 | 9.00 | 23.42 | 1.68 |
| Vitrolife AB | 286.63m | -306.87m | 2.50bn | 1.10k | -- | 2.36 | -- | 8.73 | -28.10 | -28.10 | 26.24 | 97.03 | 0.1867 | 3.48 | 6.48 | 3,293,791.00 | -19.99 | -4.57 | -20.71 | -4.78 | 58.16 | 58.38 | -107.03 | -21.89 | 2.36 | 9.24 | 0.135 | -- | 8.60 | 24.99 | -1,077.41 | -- | -7.95 | 3.30 |
Data as of Nov 14 2024. Currency figures normalised to Medacta Group SA's reporting currency: Swiss Franc CHF
14.59%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| VV Verm�gensverwaltung AGas of 30 Sep 2023 | 850.00k | 4.25% |
| Artisan Partners LPas of 31 Dec 2023 | 645.32k | 3.23% |
| UBS Asset Management Switzerland AGas of 30 Sep 2024 | 291.34k | 1.46% |
| The Vanguard Group, Inc.as of 02 Oct 2024 | 219.98k | 1.10% |
| GAM Investment Management (Switzerland) AGas of 31 Jul 2024 | 216.72k | 1.08% |
| SEB Investment Management AB (Denmark)as of 30 Sep 2024 | 152.42k | 0.76% |
| Norges Bank Investment Managementas of 30 Jun 2024 | 150.11k | 0.75% |
| Templeton Investment Counsel LLCas of 30 Sep 2024 | 134.90k | 0.68% |
| Credit Suisse Asset Management (Schweiz) AGas of 30 Apr 2024 | 133.39k | 0.67% |
| Entrepreneur Partners AGas of 30 Jun 2024 | 124.00k | 0.62% |
More ▼
Data from 30 Jun 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
